Scott Hutton

“Yeah, you know, to build off your wonderful description and introduction, as Alex said, we have five on-market tests for lung cancer positively impacting that continuum of care.”

“I'm proud to share that the Biodesics team delivered another quarter of strong growth, expanding margins, and improving operating leverage, reflecting the strength of our commercial strategy as we continue to progress towards profitability.”

“Biodethics delivered an exceptional start to 2026, with first-quarter results that demonstrate continued momentum across our commercial, operational, and strategic priorities.”

“At Biodesix, our mission is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible and address immediate clinical needs.”